re: today's NR .. Fido's alert came out @
Innovation Pharmaceuticals Files Form 10-Q Quarterly Report
BY GlobeNewswire
— 10:45 AM ET 02/11/2019
my email time stamp @
Mon, Feb 11, 2019 11:56 am
Innovation Pharmaceuticals Files Form 10-Q Quarterly Report
BEVERLY, Mass., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, announces that on February 8, 2019, it filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarter ended December 31, 2018. The filing is available on the Company’s website under the “Financials & Filings” tab.
“We’re excited about 2019 and the opportunities surrounding our drug candidates. We see an industry where large pharmas are in need of replenishing their pipelines and, to that point, there has been plenty of interest in Brilacidin due to its unique qualities, broad applications and impressive body of clinical and pre-clinical data,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “We are active in advanced discussions with a variety of pharmaceuticals companies. Our goal remains to secure a partner for advanced clinical development of Brilacidin as a new therapeutic for Oral Mucositis and Inflammatory Bowel Disease. At that time, we intend to focus our resources on the next stages of development for Brilacidin, notably dermatologic indications, and Kevetrin as a novel anti-cancer agent to build upon the completed studies.”
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources or partnering. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infections. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations, and has successfully completed a Phase 2 trial in ovarian cancer. More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, including planned Phase 3 trials of Brilacidin, our future drug development plans, other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Copyright © 2019 Innovation Pharmaceuticals, All rights reserved.
You requested to receive email alerts about Innovation Pharmaceuticals at our website http://www.ipharminc.com/
Our mailing address is:
Innovation Pharmaceuticals
100 Cummings Center, Suite 151-B
Beverly, MA 01915
trades .. currently ..
EMAIL rec'd @ 11:56AM re: News from Innovation Pharma
NEWS out @ 10:45AM
Innovation Pharmaceuticals Files Form 10-Q Quarterly Report
BY GlobeNewswire
— 10:45 AM ET 02/11/2019
my email time stamp @
Mon, Feb 11, 2019 11:56 am
Innovation Pharmaceuticals Files Form 10-Q Quarterly Report
BEVERLY, Mass., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, announces that on February 8, 2019, it filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarter ended December 31, 2018. The filing is available on the Company’s website under the “Financials & Filings” tab.
“We’re excited about 2019 and the opportunities surrounding our drug candidates. We see an industry where large pharmas are in need of replenishing their pipelines and, to that point, there has been plenty of interest in Brilacidin due to its unique qualities, broad applications and impressive body of clinical and pre-clinical data,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “We are active in advanced discussions with a variety of pharmaceuticals companies. Our goal remains to secure a partner for advanced clinical development of Brilacidin as a new therapeutic for Oral Mucositis and Inflammatory Bowel Disease. At that time, we intend to focus our resources on the next stages of development for Brilacidin, notably dermatologic indications, and Kevetrin as a novel anti-cancer agent to build upon the completed studies.”
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources or partnering. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infections. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations, and has successfully completed a Phase 2 trial in ovarian cancer. More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, including planned Phase 3 trials of Brilacidin, our future drug development plans, other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Copyright © 2019 Innovation Pharmaceuticals, All rights reserved.
You requested to receive email alerts about Innovation Pharmaceuticals at our website http://www.ipharminc.com/
Our mailing address is:
Innovation Pharmaceuticals
100 Cummings Center, Suite 151-B
Beverly, MA 01915
trades .. currently ..
12:20:30 0.14 10000 OTO
12:19:05 0.14 9909 OTO
11:58:22 0.14 675 OTO
EMAIL rec'd @ 11:56AM re: News from Innovation Pharma
11:37:24 0.14 8000 OTO
11:37:20 0.14 2500 OTO
11:37:19 0.14 5000 OTO
11:37:02 0.14 2500 OTO
11:17:57 0.145 2429 OTO
11:17:57 0.145 18500 OTO
11:17:55 0.145 5000 OTO
11:17:18 0.1499 1596 OTO
11:17:15 0.14 24000 OTO
11:17:09 0.14 5000 OTO
11:17:08 0.138 33475 OTO
11:16:53 0.138 5000 OTO
11:16:48 0.1379 40000 OTO
11:16:46 0.138 5000 OTO
11:16:42 0.135 10000 OTO .. 10000 + 17771 + 12229 = 40000
11:02:57 0.13 7500 OTO
11:02:41 0.13 17771 OTO .. 17771 + 12229 = 30000
11:02:31 0.13 5000 OTO
11:02:21 0.13 12229 OTO .. my buy (5003) @ bid bundled into (offset = 7226)
10:50:51 0.13 2774 OTO .. note 2774 + offset 7226 = 10000
10:50:25 0.1282 2700 OTO
10:46:24 0.1282 10000 OTO
NEWS out @ 10:45AM
10:07:55 0.129 2688 OTO
10:07:54 0.129 9812 OTO
10:07:35 0.129 57500 OTO
10:07:25 0.129 20000 OTO
09:51:53 0.135 3600 OTO
09:44:27 0.129 3000 OTO
09:42:30 0.128 3800 OTO
09:42:28 0.128 6200 OTO
09:42:24 0.128 5000 OTO
09:42:15 0.128 5000 OTO
09:36:18 0.14 25000 OTO
09:34:34 0.128 12975 OTO
09:34:18 0.134 1400 OTO
09:34:03 0.132 5000 OTO
09:33:59 0.1285 1000 OTO
09:33:10 0.13 1000 OTO
09:31:36 0.125 9000 OTO
09:30:46 0.125 1000 OTO
09:30:22 0.127 1500 OTO
09:30:22 0.13 32672 OTO
09:30:22 0.13 343 OTO
09:30:22 0.13 5000 OTO
09:30:22 0.13 2500 OTO
09:30:22 0.13 2725 OTO
09:30:22 0.13 1760 OTO
09:30:17 0.13 20000 OTO
09:30:13 0.13 3240 OTO
09:30:13 0.13 5000 OTO
09:30:13 0.13 7037 OTO
09:30:13 0.13 5000 OTO
09:30:13 0.13 5000 OTO
09:30:13 0.13 2723 OTO
09:30:13 0.13 277 OTO
09:30:13 0.139 3240 OTO
09:30:13 0.139 5000 OTO
09:30:13 0.139 5000 OTO
09:30:13 0.139 5000 OTO
09:30:13 0.139 2723 OTO
09:30:13 0.139 277 OTO
09:30:13 0.13 7800 OTO
09:30:13 0.13 1500 OTO
09:30:13 0.139 2000 OTO
09:30:13 0.138 2000 OTO
09:30:13 0.139 5000 OTO
09:30:13 0.138 5000 OTO
09:30:10 0.138 10000 OTO
09:30:10 0.138 3000 OTO
09:30:02 0.1325 2963 OTO
09:30:02 0.135 10000 OTO
09:30:02 0.135 357 OTO
09:30:00 0.135 5000 OTO
09:25:03 0.14 5000 OTO t trade pre mkt mirrored at open
2
